Serono Looks To Acquire Rather Than Be Acquired
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm said it will look to further expand into oncology and auto-immune diseases.
You may also be interested in...
Merck KGaA Buys Serono, Gaining U.S. Commercial Organization
Merck acquires family-owned shares representing 64.5% of Serono's capital and will launch a tender offer for the remainder, at a total value of $13.27 bil.
Merck KGaA Buys Serono, Gaining U.S. Commercial Organization
Merck acquires family-owned shares representing 64.5% of Serono's capital and will launch a tender offer for the remainder, at a total value of $13.27 bil.
Serono Labs Pleads Guilty To Criminal Conspiracy Charges In Serostim Case
Serono Inc., which reached a $704 mil. settlement with federal and state prosecutors, says its brand products will remain available under federal healthcare programs despite the guilty plea by its U.S. affiliate.